文档介绍：沙利度胺联合VAD方案化疗对多发性骨髓瘤病人细胞因子影响
作者:刘竹珍杨颉汪洪毅崔中光
【摘要】目的了解多发性骨髓瘤(MM)病人血清白细胞介素-6(IL-6)、肿瘤坏死因子α(TNF-α)的表达情况,并探讨沙利度胺联合化疗对MM病人血清IL-6、TNF-α的影响。方法用酶联免疫吸附试验(ELISA)方法测定30例正常人与79例MM病人血清IL-6、TNF-α的水平,并对MM病人不同临床分期,沙利度胺联合化疗前、后检测结果进行比较。结果 MM病人血清IL-6、TNF-α的水平明显高于正常对照组,差异有显著性(t=、,P<)。Ⅱ、Ⅲ期病人血清IL-6、TNF-α的表达水平明显高于Ⅰ期病人(F=、,q=~,P<)。55例治疗有效的MM病人血清IL-6、TNF-α的水平治疗后较治疗前明显下降(t=、,P<);治疗无效的22例MM病人治疗前、后血清IL-6、TNF-α水平无明显差异(t=、,P>)。结论血清IL-6、TNF-α的水平在MM病人中呈高表达,且与其临床分期有关;沙利度胺联合化疗可显著降低MM病人血清IL-6、TNF-α的水平;检测血清IL-6、TNF-α的水平可作为判断MM疗效及病情的辅助指标。
【关键词】多发性骨髓瘤;白细胞介素6;肿瘤坏死因子α;沙利度胺;药物疗法,联合
[ABSTRACT]ObjectiveTo observe the serum levels of IL-6 and TNF-
α in patients with multiple myeloma (MM), and explore the effects of bination chemotherapy on IL-6 and TNF-α. MethodsThe serum IL-6 and TNF-α in 79 MM patients and 30 normal controls were determined by ELISA, and the results of the patients in different stages as well as before and after therapy The concentrations of IL-6 and TNF-α in MM group were significantly higher than those in the control (t=,;P<). The levels of IL-6 and TNF-α in stage Ⅲ and stage Ⅱpatients were higher than those of stageⅠ(F=, ;q=-;P<). Of 55 patients responding well to the therapy, levels of IL-6 and TNF-α declined pared with before treatment (t=,;